In critically ill patients undergoing PCI with microaxial flow pumps, oral P2Y12 inhibitors only versus cangrelor showed no significant difference in clinical outcomes (26.4% vs 33.0%, p=0.2).
Observational
Does cangrelor improve outcomes or reduce bleeding compared to oral P2Y12 inhibitors only in critically ill patients requiring percutaneous coronary interventions supported by microaxial flow pumps?
In critically ill patients undergoing PCI supported by microaxial flow pumps, cangrelor did not significantly differ from oral P2Y12 inhibitors alone in early stent thrombosis or overall outcomes.
Absolute Event Rate: 26.4% vs 33%
p-value: p=0.2
Background: i cangrelor offers rapid and reversible platelet inhibition, but its role in this setting remains unclear. Objective: i only versus loading with cangrelor. Methods: i. Periprocedural major bleeding (BARC ≥ 3) within 48 h, in-hospital major adverse cardiovascular events (MACE) and 6-month MACE were analyzed. Results: i group (26.4% versus 33.0%, p = 0.2). Early stent thrombosis rates were relatively low and not significantly different (1.0% versus 2.1%, p = 0.6). Presentation with cardiogenic shock was associated with a higher risk for post-PCI major bleeding (OR 7.09, 95%CI 2.97-18.49) and 6-month MACE (HR 2.01, 95% CI 1.01-3.97). Conclusion: i, with consistent results after adjustment. Given the observational design, these findings require confirmation in randomized trials.
Schaffner et al. (Tue,) conducted a observational in Critically ill patients requiring percutaneous coronary interventions supported by microaxial flow pumps. Oral P2Y12 inhibitors only vs. Cangrelor was evaluated on Periprocedural major bleeding (BARC ≥ 3) within 48 h, in-hospital MACE and 6-month MACE (p=0.2). In critically ill patients undergoing PCI with microaxial flow pumps, oral P2Y12 inhibitors only versus cangrelor showed no significant difference in clinical outcomes (26.4% vs 33.0%, p=0.2).